Selecting the right patient for tumor therapy

Research output: Contribution to journalShort survey

23 Scopus citations


Two clinical studies have identified mutations affecting the EGF receptor in lung cancers from patients who respond robustly to gefitinib, a small-molecule inhibitor of the receptor tyrosine kinase. This work highlights the importance of conducting clinical trials with an eye to delivering molecule-targeted therapeutics to those patients most likely to benefit.

Original languageEnglish (US)
Pages (from-to)577-578
Number of pages2
JournalNature Medicine
Issue number6
Publication statusPublished - Jun 1 2004


ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this